Key facts
- It has raised $5.0M; the latest was Later Stage VC in Feb 2026.
- Notable investors include FJ Labs, TA Ventures, ROM Utrecht Region, Infinitas Capital, TruVenturo — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Cleara Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Cleara Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cleara Biotech
Operator of a biotechnology company intended to eliminate senescent cells to treat age-related pathologies. The company offers therapeutics that can be used to remove senescence-like cancer cells that are a cause of therapy resistance in terminal cancer, enabling physicians to treat their patients effectively.
- Sector
- Healthcare
- HQ
- Utrecht, Netherlands
- Founded
- 2018
- Employees
- 9
- Website
- clearabiotech.com/
- Ownership
- Privately Held (backing)
Cleara Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cleara Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cleara Biotech in its N-PORT filings yet. We sweep new filings monthly.